Eli Lilly & Co. (LLY)
NYSE: LLY · Pharmaceutical Preparations · Indianapolis, IN · filing with the SEC since 1994
Grade7.5
◀ Past 8.1● Present 7.8▶ Future 6.3
Who owns Eli Lilly & Co.
As filed with the SECHolders of 5% or more
3
Lilly Endowment, Inc. holds 9.6% of Common Stock, Without Par Value, as its SCHEDULE 13G/A filed Oct 19, 2026 says.
Directors and officers
26
report now, of 58 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Lilly Endowment, Inc.
SCHEDULE 13G/A · filed Oct 19, 2026 · Common Stock, Without Par Value · 9.6% in Jul 23, 2026
Vanguard Capital Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
PNC Financial Services Group
SCHEDULE 13G/A · filed Feb 7, 2025 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 8.55% in Oct 30, 2025
What LLY reports owning in othersstakes of 5% or more, and other ties
TRex Bio, Inc.
SCHEDULE 13D · filed Oct 16, 2026 · Common Stock, par value $0.0001 per share
ProQR Therapeutics N.V. PRQR
SCHEDULE 13G/A · filed Jul 24, 2026 · Ordinary Shares, nominal value 0.04 EUR per share
Aktis Oncology, Inc. AKTS
SCHEDULE 13D · filed Jan 15, 2026 · Common Stock, $0.0001 par value per share
Ionetix Corp / DE /
SCHEDULE 13G · filed Jul 24, 2026 · Common Stock, par value $0.0001 per share
Scribe Therapeutics Inc. SCTX
SCHEDULE 13D · filed Jul 30, 2026 · Common stock, $0.001 par value per share
Immunocore Holdings plc IMCR
SCHEDULE 13G/A · filed Oct 3, 2025 · Ordinary Shares · reported falling below 5%
Other ties the annual report names
Verve Therapeutics, Inc.
A company bought · acquisition · Jul 2025 · owns, named in the 10-K filed Feb 12, 2026
NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC
A company bought · acquisition · May 2024 · owns, named in the 10-K filed Feb 12, 2026
Point Biopharma Global Inc
A company bought · acquisition · Dec 2023 · owns, named in the 10-K filed Feb 12, 2026
158 subsidiaries in 55 countries, from the list filed with the 10-K filed Feb 12, 2026.
Insider tradesForm 4
6sales
0purchases
6sales on a scheduled plan
4people selling
$26.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 59 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lilly Endowment Inc | 10% owner | 172 | $77.64B | 0 | 0 | $0 |
| Hakim Anat | EVP, GC & Secretary | 2 | $13.0M | 2 | 0 | $0 |
| Jonsson Patrik | EVP & President, LLY Int'l | 1 | $7.6M | 1 | 0 | $0 |
| Zakrowski Donald A | SVP, Finance, & CAO | 2 | $3.4M | 2 | 0 | $0 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | 1 | $2.9M | 1 | 0 | $0 |